DDInter1673 DDInter1544
Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Like all NS3/4A inhibitors, simeprevir is a serine protease inhibitor in similarity to and but is classified as a second generation protease inhibitor. This class of antiviral drugs were the first direct acting antivirals approved but are associated with lower cure rates than newer drugs. Broad use of simeprevir occurred when it was used in combination with a newer drug,. Inhibiting HCV NS3/4A protease in a potent and highly specific manner, simeprevir is a direct-
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Simeprevir {u} (Compound) binds {v} (Gene) ALB
Simeprevir {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
Simeprevir {u} (Compound) causes {v} (Side Effect) Mediastinal disorder
Simeprevir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Talazoparib
Simeprevir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Simeprevir {u} may lead to a major life threatening interaction when taken with {v} Aminolevulinic acid
Simeprevir {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Simeprevir (Compound) binds ALB (Gene)
Simeprevir (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class)
Simeprevir (Compound) causes Mediastinal disorder (Side Effect)
Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Simeprevir may lead to a major life threatening interaction when taken with Aminolevulinic acid
Simeprevir may lead to a major life threatening interaction when taken with Enzalutamide